Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2972

1.

Investigation of MDM2 Oncogene Copy Number Alterations in Cases With Chronic Lymphocytic Leukemia.

Darbaş Ş, Aydın Ç, Salim O, Berker Karauzum S.

Turk J Haematol. 2018 Oct 16. doi: 10.4274/tjh.2018.0270. [Epub ahead of print] No abstract available.

2.

MDMX under stress: the MDMX-MDM2 complex as stress signals hub.

de Polo A, Vivekanandan V, Little JB, Yuan ZM.

Transl Cancer Res. 2016 Dec;5(6):725-732. doi: 10.21037/tcr.2016.12.18.

3.

Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine.

Qin JJ, Li X, Hunt C, Wang W, Wang H, Zhang R.

Genes Dis. 2018 Jul 20;5(3):204-219. doi: 10.1016/j.gendis.2018.07.002. eCollection 2018 Sep. Review.

4.

The frequency of TP53 R72P and MDM2 309T>G polymorphisms in Iranian infertile men with spermatogenetic failure: A case-control study.

Ebrahim Abadi Z, Khademi Bami M, Golzadeh M, Kalantar SM, Sheikhha MH.

Int J Reprod Biomed (Yazd). 2018 Aug;16(8):491-496.

5.

Photoactivation of MDM2 Inhibitors: Controlling Protein-Protein Interaction with Light.

Hansen MJ, Feringa FM, Kobauri P, Szymanski W, Medema RH, Feringa BL.

J Am Chem Soc. 2018 Oct 17;140(41):13136-13141. doi: 10.1021/jacs.8b04870. Epub 2018 Oct 4.

PMID:
30284823
6.

Primary undifferentiated pleomorphic cardiac sarcoma with MDM2 amplification presenting as acute left-sided heart failure.

Watson R, Frye J, Trieu M, Yang MX.

BMJ Case Rep. 2018 Sep 30;2018. pii: bcr-2018-226073. doi: 10.1136/bcr-2018-226073.

7.

Targeting resistance against the MDM2 inhibitor RG7388 in glioblastoma cells by the MEK inhibitor trametinib.

Berberich A, Kessler T, Thomé CM, Pusch S, Hielscher T, Sahm F, Oezen I, Schmitt LM, Ciprut S, Hucke N, Rübmann P, Fischer M, Lemke D, Breckwoldt MO, von Deimling A, Bendszus M, Platten M, Wick W.

Clin Cancer Res. 2018 Oct 1. pii: clincanres.1580.2018. doi: 10.1158/1078-0432.CCR-18-1580. [Epub ahead of print]

PMID:
30274984
8.
9.

Advanced Glycation End Products Increase MDM2 Expression via Transcription Factor KLF5.

Wang P, Lu YC, Li YF, Wang L, Lee SC.

J Diabetes Res. 2018 Sep 9;2018:3274084. doi: 10.1155/2018/3274084. eCollection 2018.

10.

Role of screening colonoscopy for colorectal tumors in Helicobacter pylori-related chronic gastritis with MDM2 SNP309 G/G homozygous: A prospective cross-sectional study in Thailand.

Tongtawee T, Simawaranon T, Wattanawongdon W.

Turk J Gastroenterol. 2018 Sep;29(5):555-560. doi: 10.5152/tjg.2018.17608.

PMID:
30260777
11.

Mdm2-p53-SF1 pathway in ovarian granulosa cells directs ovulation and fertilization by conditioning oocyte quality.

Haraguchi H, Hirota Y, Saito-Fujita T, Tanaka T, Shimizu-Hirota R, Harada M, Akaeda S, Hiraoka T, Matsuo M, Matsumoto L, Hirata T, Koga K, Wada-Hiraike O, Fujii T, Osuga Y.

FASEB J. 2018 Sep 27:fj201801401R. doi: 10.1096/fj.201801401R. [Epub ahead of print]

PMID:
30260703
12.

Troxerutin subdues hepatic tumorigenesis via disrupting the MDM2-p53 interaction.

Thomas NS, George K, Selvam AAA.

Food Funct. 2018 Oct 17;9(10):5336-5349. doi: 10.1039/c8fo01111g.

PMID:
30259932
13.

Correction: Solid-state nanopore analysis on conformation change of p53TAD-MDM2 fusion protein induced by protein-protein interaction.

Chae H, Kwak DK, Lee MK, Chi SW, Kim KB.

Nanoscale. 2018 Oct 4;10(38):18423. doi: 10.1039/c8nr90204f.

PMID:
30256376
14.

The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.

Liao G, Yang D, Ma L, Li W, Hu L, Zeng L, Wu P, Duan L, Liu Z.

Eur J Med Chem. 2018 Nov 5;159:1-9. doi: 10.1016/j.ejmech.2018.09.044. Epub 2018 Sep 18. Review.

PMID:
30253242
15.

Double amplifications of CDK4 and MDM2 in a gastric inflammatory myofibroblastic tumor mimicking cancer with local invasion of the spleen and diaphragm.

He J, Zhao X, Huang C, Zhou X, You Y, Zhang L, Lu C, Yao F, Li S.

Cancer Biol Ther. 2018 Sep 25:1-6. doi: 10.1080/15384047.2018.1480290. [Epub ahead of print]

PMID:
30252584
16.

Potential use of compounds from sea cucumbers as MDM2 and CXCR4 inhibitors to control cancer cell growth.

Wargasetia TL, Permana S, Widodo N.

Exp Ther Med. 2018 Oct;16(4):2985-2991. doi: 10.3892/etm.2018.6588. Epub 2018 Aug 7.

17.

The Study of MDM2 rs937283 Variant and Cancer Susceptibility in a Central Chinese Population.

Chen B, Wang J, Wang J, Zhang J, Gu X, Feng X.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818801550. doi: 10.1177/1533033818801550.

18.

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.

Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS.

Oncotarget. 2018 Sep 4;9(69):33232-33243. doi: 10.18632/oncotarget.26075. eCollection 2018 Sep 4.

19.

Trisenox disrupts MDM2-DAXX-HAUSP complex and activates p53, cell cycle regulation and apoptosis in acute leukemia cells.

Kumar S, Brown A, Tchounwou PB.

Oncotarget. 2018 Sep 4;9(69):33138-33148. doi: 10.18632/oncotarget.26025. eCollection 2018 Sep 4.

20.

Inhibition of p53-Murine Double Minute 2 (MDM2) Interactions with 3,3'-Spirocyclopentene Oxindole Derivatives.

Gicquel M, Gomez C, Garcia Alvarez MC, Pamlard O, Guérineau V, Jacquet E, Bignon J, Voituriez A, Marinetti A.

J Med Chem. 2018 Oct 8. doi: 10.1021/acs.jmedchem.8b01137. [Epub ahead of print]

PMID:
30221935

Supplemental Content

Support Center